BSX Stock Recent News

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Boston Scientific Corp.'s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.

Medical device maker Boston Scientific beat Wall Street expectations for fourth-quarter profit on Wednesday, helped by strength in its heart devices unit.

Boston Scientific said on Wednesday the U.S. Food and Drug Administration has approved the company's device for a type of heart condition.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Boston Scientific (BSX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

J&J, Merck and Boston Scientific kicked off the year's biggest medical conference with a trio of takeovers. AMAM stock and HARP stock soared.

The move will expand Boston's product portfolio in its urology business.